Bovine Respiratory Disease Biomarker Kits for Targeted Antibiotic Use
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Bovine respiratory disease (BRD) poses a significant economic burden on the beef industry due to high morbidity and mortality rates, with current diagnostic methods being subjective and therapeutic options, such as antimicrobial treatments, contributing to antibiotic resistance and increased costs.
Innovation Solution
The development of methods and kits for selecting cows to treat for BRD based on biomarkers associated with specific bacteria in nasal swab, nasopharyngeal swab, and bronchoalveolar lavage samples, allowing for predictive analysis of BRD likelihood and diagnosis, thereby enabling targeted antibiotic use and reducing unnecessary treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum antibiotics are used to treat BRD, then mortality rates decrease, but antibiotic resistance increases and treatment costs increase
Solution Approach 1:
The patent applies preliminary action by using biomarker analysis (such as inflammatory markers like haptoglobin, alpha-1-acid glycoprotein, and C-reactive protein) to identify high-risk calves before they develop clinical BRD symptoms. This allows targeted antibiotic treatment only for calves most likely to benefit, preventing unnecessary antibiotic exposure in low-risk animals and thereby reducing antibiotic resistance development while maintaining effective treatment for those who need it
Solution Approach 2:
The patent applies local quality by transitioning from uniform herd-wide antibiotic treatment to individualized targeted treatment based on each calf's biomarker profile and risk assessment. This localized approach ensures antibiotics are applied only where needed (in high-risk individuals) rather than broadly across the entire herd, reducing overall antibiotic pressure and resistance selection while maintaining mortality control in treated animals
2Loss of substance
If biomarker analysis is implemented for targeted treatment, then antibiotic use decreases, but diagnostic complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the diagnostic process into distinct, manageable components: (1) sample collection (nasal swab, blood sample), (2) specific biomarker measurement (haptoglobin, alpha-1-acid glycoprotein, C-reactive protein, cytokines), and (3) risk classification based on predefined thresholds. This segmented approach simplifies implementation compared to comprehensive microbiome sequencing, allowing gradual adoption and reducing overall diagnostic complexity while still enabling targeted treatment to reduce antibiotic use
Solution Approach 2:
The patent uses measurable biomarkers (haptoglobin, alpha-1-acid glycoprotein, C-reactive protein) as intermediaries that bridge the gap between complex microbial community changes and simple treatment decisions. These biomarkers serve as surrogate indicators that translate complex respiratory tract microbial and inflammatory states into quantifiable values that can be measured with standard laboratory techniques, avoiding the need for complex direct microbiome analysis while still enabling risk stratification and targeted antibiotic use reduction
3Measurement precision
If clinical diagnosis based on subjective observations is used, then treatment costs increase, but diagnostic precision remains low
Solution Approach 1:
The patent applies mechanics substitution by replacing subjective clinical observation (visual inspection,听诊) with objective biochemical measurement of biomarkers in blood or nasal secretions. Instead of relying on veterinarian expertise and sensory judgment, the system uses laboratory-measured concentrations of haptoglobin, alpha-1-acid glycoprotein, C-reactive protein, and other biomarkers to objectively determine treatment necessity, improving diagnostic precision while reducing unnecessary treatments and associated costs
Data Source
AI summary
Sets of bacterial features were identified in the nostrils, nasopharynx, and lungs of cows that can be used to predict the likelihood that a cow will develop bovine respiratory disease (BRD) or to diagnose BRD. The present invention provides methods and kits for selecting cows to treat for BRD based on the levels of these biomarkers in the respiratory microbiome. Using these methods and kits, producers may selectively treat cows deemed to be at risk for BRD, saving money and decreasing antibiotic use.